If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
99
results.
Updated on
12/01/2026 [06:56:00]
Results 50 to 75 of 99
Absstract of: US2025366743A1
Methods, systems, and devices for regulating blood glucose such as implantable encapsulated devices optionally with insulin and/or glucagon secreting cells in combination with glucose sensors and insulin infusion systems. For example, encapsulation devices may be connected to an insulin infusion pump for distribution of insulin. The insulin infusion pump may feature an insulin pouch fluidly connected to an insulin pump (or a syringe) and a glucose sensor separate from the encapsulation device. The system may feature an additional implantable device comprising insulin and glucagon secreting cells.
Absstract of: US2025366749A1
Disclosed herein are devices, systems, and methods for a continuous analyte sensor, such as a continuous glucose sensor. In certain embodiments disclosed herein, various in vivo properties of the sensor's surroundings can be measured. In some embodiments, the measured properties can be used to identify a physiological response or condition in the body. This information can then be used by a patient, doctor, or system to respond appropriately to the identified condition.
Absstract of: US2025367370A1
A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body. The pump can be selectively attached to the retention frame and used to deliver medicament either through a cannula to an infusion site directly beneath the retention frame or through tubing to an infusion site displaced from the retention frame.
Absstract of: WO2025247647A1
The invention provides an apparatus for non-invasive in vivo measurement by Raman spectroscopy of analyte presence and/or concentration, such as glucose, in the skin of a subject, the apparatus comprising; a planar probe having one or more optical sources for irradiating a sample such as the skin of a subject; a spectrometer configured to receive Raman scattered radiation collected from the sample in response to the received radiation from the one or more optical sources; a numerical aperture controller to determine the numerical aperture of the apparatus, and thereby control the input light received by the spectrometer.
Absstract of: US2025366742A1
One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved.
Absstract of: AU2025267469A1
22222883_1 (GHMatters) P120626.AU.1 In some aspects, a system is provided for gathering and processing sensor data to identify a risk of impacting or causing a venous leg ulcer, wherein the system includes computer- readable memory and one or more processors and is configured to: obtain sensor feature data including a set of feature data representing output of a user sensor configured to be worn on a limb of a user; determine an activity classification using the set of feature data and an activity classification model, wherein the activity classification model includes a decision tree configured to assign the set of feature data to one of a plurality of different activity classifications wherein the different activity classifications comprises: i a first activity classification representing motion of the limb; ii a second activity classification representing no motion of the limb with static weight such as standing; and iii a third activity classification representing that the user is lying down; wherein the system is further configured to generate display data representing the activity classification; and transmit the display data to a computing device configured to present the display data. ov o v
Absstract of: US2025367366A1
An insulin monitoring system includes one or more processors, one or more computer-readable storage devices, and program instructions stored on at least one of the one or more storage devices for execution by at least one of the one or more processors. The program instructions include: first program instructions to track, in real time, the amount of insulin active in a patient; second program instructions to calculate the amount of insulin need of the patient by tracking the patient's metabolic states; third program instructions to compare the insulin active in the patient with the insulin need of the patient; and fourth program instructions to determine an insulin fault level based on the comparison.
Absstract of: US2025367380A1
Techniques for automatic device configuration are disclosed herein. In some embodiments, the techniques involve receiving patient data by one or more processors of a cloud-based server device. The techniques further involve obtaining, by the cloud-based server device, and based on the patient data, a value of a total daily dose of insulin for the specific patient. The techniques further involve automatically selecting, by the cloud-based server device, before the medical device has been set up to deliver insulin to the specific patient, a therapy configuration for the medical device. The techniques further involve determining, by the cloud-based server device, a set of therapy settings for the selected therapy configuration for the specific patient based upon the value of the total daily dose. The techniques further involve automatically configuring, via a non-medical device, the medical device with the set of therapy settings in a startup mode.
Absstract of: US2025367371A1
A hybrid bioelectronic implantable device containing engineered cells for delivery of therapeutic agents to a subject to treat a medical condition of the subject. The device comprises an implantable device implantable inside the subject's body, wherein the implantable device comprises at least one cell housing containing the engineered cells; and an optical stimulating system within the at least one cell housing, wherein the optical stimulating system is configured to control production of at least one type of therapeutic agents by the engineered cells; wherein the medical condition of the subject comprises one of a sleep disorder, a circadian rhythm disorder, neuro disorders, infertilities, diabetes, obesity, eating disorders, cancers, bone marrow disorders, autoimmune disorders, addictive disorders.
Absstract of: EP4657456A2
Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.
Absstract of: EP4656127A2
The present invention relates to a continuous blood glucose measurement apparatus which, by manufacturing a body-attachable unit in an assembled state inside an applicator, minimizes the additional work by a user for attaching the body-attachable unit to the body and thus enables the body-attachable unit to be attached to the body simply by means of operating the applicator, and, by providing a wireless communication chip on the body-attachable unit and enabling communication with an external terminal, can be used in a simple and convenient manner without the additional work of connecting a separate transmitter and enables easier maintenance and management, and, by having the operation of the body-attachable unit initiated by means of the user's manipulation after being attached to the body, enables the operation initiation point to be adjusted to an appropriate point as necessary by the user, enables an operation initiation in a stabilized state and thus enables more accurate blood glucose measurement.
Absstract of: EP4656133A2
The present invention relates to a body attachment unit for continuous glucose monitoring. The present invention provides a body attachment unit for continuous glucose monitoring, wherein: the body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus separate additional work is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by a user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Absstract of: EP4657457A1
One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved.
Absstract of: GB2641380A
An apparatus 2 for non-invasive in vivo measurement by Raman spectroscopy of analyte presence and/or concentration, such as glucose, in the skin of a subject is provided. The apparatus comprises a planar probe 8 having one or more optical sources (151, Fig. 1C) for irradiating a sample; a spectrometer 4 configured to receive Raman scattered radiation collected from the sample; a numerical aperture controller to determine the numerical aperture of the apparatus, and thereby control the input light received by the spectrometer. The numerical aperture controller may comprise an aperture stop (14, Fig 2A) within the spectrometer. The numerical aperture controller may be part of the probe for example a light absorbing region (25, Fig. 2C) around an opening in the PCB layer for receiving a Raman signal. Alternatively, the numerical aperture of an optical fibre interface (36, Fig. 5C) or buried light guide (54, Fig. 6B) may be selected; or the combination of a micro lens array (68, Fig. 7A) and pinhole array (64, Fig. 7B) in the probe may be selected to determine the numerical aperture.
Absstract of: EP4656125A1
One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user.
Absstract of: NZ803295A
Prior art glucose measurement devices have issues relating to poor user experiences where manual multiple steps are required to obtain readings. Herein described is a glucose measurement apparatus, comprising a plunger body (300) disposed inside the main case and configured to move the body attachable unit from a first location to a second location, a needle unit (550) separably coupled to the body attachable unit, a return prevention unit (340, 161) configured to block returning movement of the plunger body to the first position after the plunger body is moved to the second position is included in the main case, and the needle unit (550) is configured to move together with the body attachable unitas the body attachable unit being moved from the first location to the second location, and is configured to move toward the first location after the body attachable unit is inserted into the body.
Absstract of: US2025360273A1
An insulin infusion system is provided with a manual insertion device having a dual retraction spring (230) configuration for automatic introducer needle (222) retraction. A button (200) of the insertion device is used to insert the introducer needle (222) and catheter (202), and once the introducer needle (222) and catheter (202) have been fully inserted, a rotating engagement releases the dual retraction springs (230) such that the introducer needle (222) automatically retracts, leaving the catheter (202) in the body of the user. An end of the introducer needle (222) remains in the inserted catheter (202) and/or in the septum (206) of the inserted catheter (202) to provide an uninterrupted fluid path.
Absstract of: US2025359762A1
Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from the palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0.9216 when compared to a standard electrochemical glucose analysis test.
Absstract of: WO2025244151A1
The present invention relates to a non-invasive glucose measurement device and method. To this end, the non-invasive glucose measurement device according to one embodiment of the present invention may comprise: a light irradiation unit which is positioned beneath an inner lower case disposed beneath an inserted finger, and which includes a first light-emitting element and a second light-emitting element for irradiating light toward the finger placed on the inner lower case; a light reception unit which is disposed on an inner upper case disposed on the finger, and which includes a first light-receiving element and a second light-receiving element for receiving the light irradiated from the light irradiation unit and transmitted through the finger; a motor unit including a first motor disposed at one side of the inner lower case and a second motor disposed at the other side of the inner lower case; a pressure sensor unit which is disposed beneath the inner lower case, and which includes a first pressure sensor and a second pressure sensor for measuring pressure applied by the finger; and a processor for measuring glucose by using the amount of light received through the light reception unit.
Absstract of: US2025364143A1
A method for determination of an event-related index for a human user, where:one provides time-based data for an observation period, with:time-based blood glucose data for the totality of the observation period, said time-based blood glucose data being derived from a continuous glucose monitor,time-based event data for the event period,a computerized index determination module determines said event-related index as a composite index of the blood glucose data related to the event period and the blood glucose data outside the event period.
Absstract of: US2025359828A1
The technologies discussed herein relate to a biometrics system comprising one or more processors, computer storage memory having computer-executable instructions, surgically implantable devices, and wearables (e.g., an apparel item configured for an upper torso, an apparel item configured for a lower torso, a sock, a headband, other types of wearables, or one or more combinations thereof) having one or more biometric sensors (e.g., a heart rate sensor, a sweat sensor, a glucose sensor, other types of biometric sensors, or one or more combinations thereof) and one or more sensation devices (e.g., a plurality of visible light sources, a haptic feedback device, other types of sensation devices, or one or more combinations thereof). The wearables may also include one or more environmental sensors. The wearables emulate, transmogrify, or enhance one or more human senses using the one or more sensation devices based on biometric data or environmental data received.
Absstract of: US2025359790A1
A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.
Absstract of: EP4653033A1
Provided is a safety insulin pen needle. The safety insulin pen needle includes a needle hub, a protective sleeve, a needle cap, and a limiting block. A fixed post protruding along with an injection needle is disposed on the needle hub. A snap-fit step is disposed on the surface of the fixed post. The injection needle is inserted through the protective sleeve. A spring is clamped between the protective sleeve and the needle hub such that the protective sleeve is axially movable relative to the needle hub to expose or cover a needle tip of the injection needle. A protruding edge is disposed on an outer wall of the protective sleeve. A first limiting step and a second limiting step are disposed on an inner wall of the protective sleeve along a direction in which the injection needle penetrates. The inner diameter of the second limiting step is smaller than the inner diameter of the first limiting step. The needle cap is fixedly assembled with the needle hub and encloses the protective sleeve within the needle cap. The needle cap is provided with a through-hole allowing the protective sleeve to extend out. The through-hole limits the protruding edge. The limiting block is located in an inner cavity of the protective sleeve and is sleeved on the injection needle. A first end of the limiting block is provided with a claw that engages with the snap-fit step, and a second end of the limiting block cooperates with the first limiting step or the second limiting step to stop the protec
Absstract of: ZA202305438B
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).
Nº publicación: ES3042625T3 21/11/2025
Applicant:
I SENS INC
I-sens, Inc
Absstract of: AU2025223826A1
A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. The plunger body is configured to be decoupled from the first position and to be moved to a second position in an injecting direction. The sensor module is coupled to one end portion of the plunger body to be moved integrally with the plunger body as the plunger body being moved toward the second position. An adhesive layer is attached to a lower surface of the sensor module to attach the sensor module to the human body, and is configured to be moved together with the sensor module as the plunger body being moved toward the second position. A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. T
BOPI
Electronic site
